Cell therapies in diabetes: distinguish approved islet therapy from research products

Begin with diabetes type, complications, current management and the clinical problem being addressed. Type 1 diabetes involves loss of insulin-producing beta cells; type 2 diabetes has different and heterogeneous mechanisms. Results from an islet-replacement product for a narrow type 1 population cannot be transferred to type 2 diabetes or to a generic MSC infusion.

FDA approved Lantidra (donislecel-jujn), an allogeneic pancreatic-islet cellular therapy made from deceased-donor pancreatic cells, for selected adults with type 1 diabetes who cannot approach target HbA1c because of repeated severe hypoglycaemia despite intensive management and education. It is infused into the hepatic portal vein and requires immunosuppression; the FDA review reports serious procedure- and immunosuppression-related adverse reactions. This is not a general stem-cell cure for diabetes.

Stem-cell-derived islet products, encapsulated cells, gene-edited cells and immune-modulating cell products have different development programmes and may remain investigational. Ask for the exact product, trial phase, regulator identifier, eligibility, immunosuppression or device requirements and primary endpoint. A company announcement, trial listing or insulin-production biomarker is not marketing authorisation or proof of durable insulin independence.

Evaluate studies through the comparator, severe-hypoglycaemia outcomes, HbA1c, insulin use, quality of life, adverse events, graft function and follow-up. Report how many participants received each number of administrations and how many discontinued immunosuppression or lost graft function. Do not replace insulin or established diabetes care outside a specialist-directed protocol.

Verify the FDA Lantidra product record and its approved indication, and use the ISSCR clinical-translation guidelines when assessing a research proposal. An endocrinologist and, where relevant, a transplant specialist independent of the selling provider should review established alternatives and study suitability.

Sources & further reading

• Stem-cell trials registry (ClinicalTrials.gov) ↗
• Peer-reviewed research (PubMed) ↗
• ISSCR — patient resources ↗
• FDA — consumer guidance ↗
• EMA — ATMP framework ↗

Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.